Quarterly Activity Report & Appendix 4C

Race Oncology Limited has released its Q2 FY2024 quarterly report for the period ended 31 December 2023.

Highlights include:

• Dr Daniel Tillett appointed CEO and a funded clinical program focused on cardioprotection, m6A RNA & AML announced

• Interim Phase 2 trial results were presented at the prestigious American Society of Hematology 65th Annual Meeting describing the use of bisantrene in combination with fludarabine and clofarabine that induced a clinical response in 6 of 15 (40%) evaluable patients with advanced relapsed or refractory Acute Myeloid Leukaemia

• Race issued a 1 for 20 bonus and piggyback option series to existing shareholders to raise up to $36.6 million to fund future clinical activities in cardioprotection, m6A RNA & AML.